
    
      This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of PT2385 in
      patients with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor
      (as defined by RECIST 1.1). PT2385 will be administered orally and treatment will be
      continuous. Changes in VHL disease-associated non-ccRCC tumors will also be evaluated.
    
  